Selventa signs research agreement with Janssen

The companies will develop disease models using diverse biologic data to elaborate disease-relevant mechanisms and find out potential new drug discovery opportunities.

Selventa will leverage molecular patient data and computational methods for mechanistic understanding of disease biology and unambiguously identify patient subsets based on the disease-driving mechanisms.

The research will focus on assessment of single and combination therapies, segmentation of potential responder and non-responder populations, evaluation of alternative indications, and optimization of clinical trial design through stratification biomarker panels.

Selventa president and CEO David de Graaf said that building comprehensive disease models and investigating different molecular mechanisms may provide key data-driven foundations for appropriate selection of druggable mechanisms within a disease.